Harvei S, Solheim O
Cancer. 1981 Oct 15;48(8):1719-23. doi: 10.1002/1097-0142(19811015)48:8<1719::aid-cncr2820480806>3.0.co;2-j.
Reports on the varying effect of adjuvant chemotherapy in the treatment of osteosarcomas led the authors to analyze survival experience in osteosarcomas on a national level. Data from the Norwegian Cancer Registry, covering the total population of Norway (4 million), were analyzed. There appeared to be no significant changes in survival from 1953 to 1975. For the period 1975-1977, the 48-month survival time improved from 25% for the three preceding five-year periods to 47%. Possible changes in diagnostics and reporting seem to have had little effect on the occurrence of the disease. Improvement in short-time survival was therefore considered attributable to adjuvant chemotherapy introduced in 1975 and its accompanying procedures of early amputation, intensified clinical follow-up, and possible surgery on metastases. The partial contribution of these treatment elements could not be ascertained.
关于辅助化疗在骨肉瘤治疗中效果各异的报告，促使作者在全国范围内分析骨肉瘤的生存情况。对来自挪威癌症登记处、涵盖挪威全体人口（400万）的数据进行了分析。1953年至1975年期间，生存率似乎没有显著变化。在1975 - 1977年期间，48个月的生存时间从之前三个五年期的25%提高到了47%。诊断和报告方面可能的变化似乎对该疾病的发生影响不大。因此，短期生存率的提高被认为归因于1975年引入的辅助化疗及其伴随的早期截肢程序、强化的临床随访以及对转移灶可能进行的手术。这些治疗因素各自的具体贡献尚无法确定。
